Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Case Comprehensive Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00278174 |
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer.
PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.
Condition | Intervention | Phase |
---|---|---|
Kidney Cancer |
Biological: recombinant interferon alpha-1b |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma |
Estimated Enrollment: | 30 |
Study Start Date: | February 2005 |
Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is an open-label study.
Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence of unacceptable toxicity or disease progression.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed predominantly renal clear cell carcinoma
Good- or intermediate-risk category as defined by having ≤ 2 of the following factors:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
No concurrent steroid use except ongoing replacement therapy with physiologic doses of corticosteroids
United States, Ohio | |
Cleveland Clinic Taussig Cancer Center | Recruiting |
Cleveland, Ohio, United States, 44195 | |
Contact: Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100 |
Study Chair: | Ronald M. Bukowski, MD | The Cleveland Clinic |
Study ID Numbers: | CDR0000446100, CASE-CCF-7752, CASE-CCF-15804 |
Study First Received: | January 16, 2006 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00278174 History of Changes |
Health Authority: | Unspecified |
stage IV renal cell cancer recurrent renal cell cancer clear cell renal cell carcinoma |
Interferon-alpha Urinary Tract Neoplasm Interferon Type I, Recombinant Kidney Cancer Immunologic Factors Interferons Urogenital Neoplasms Urologic Neoplasms Angiogenesis Inhibitors Antiviral Agents Recurrence |
Carcinoma Renal Cancer Urologic Diseases Kidney Neoplasms Carcinoma, Renal Cell Clear Cell Renal Cell Carcinoma Kidney Diseases Interferon Alfa-2a Adenocarcinoma Neoplasms, Glandular and Epithelial |
Anti-Infective Agents Interferon Type I, Recombinant Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Urogenital Neoplasms Urologic Neoplasms Neoplasms by Site Urologic Diseases Kidney Neoplasms Therapeutic Uses Growth Inhibitors Kidney Diseases Angiogenesis Modulating Agents |
Interferon-alpha Neoplasms by Histologic Type Growth Substances Interferons Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Carcinoma Neoplasms Carcinoma, Renal Cell Adenocarcinoma Interferon Alfa-2a Neoplasms, Glandular and Epithelial |